- Home
- GPRE vs ERAS Comparison
GPRE vs ERAS Comparison
Compare GPRE & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRE
- ERAS
- Stock Information
- Founded
- GPRE 2004
- ERAS 2018
- Country
- GPRE United States
- ERAS United States
- Employees
- GPRE N/A
- ERAS N/A
- Industry
- GPRE Major Chemicals
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- GPRE Industrials
- ERAS Health Care
- Exchange
- GPRE Nasdaq
- ERAS Nasdaq
- Market Cap
- GPRE 790.7M
- ERAS 719.0M
- IPO Year
- GPRE N/A
- ERAS 2021
- Fundamental
- Price
- GPRE $11.32
- ERAS $2.70
- Analyst Decision
- GPRE Strong Buy
- ERAS Strong Buy
- Analyst Count
- GPRE 9
- ERAS 6
- Target Price
- GPRE $26.06
- ERAS $6.08
- AVG Volume (30 Days)
- GPRE 1.4M
- ERAS 1.7M
- Earning Date
- GPRE 10-31-2024
- ERAS 11-12-2024
- Dividend Yield
- GPRE N/A
- ERAS N/A
- EPS Growth
- GPRE N/A
- ERAS N/A
- EPS
- GPRE N/A
- ERAS N/A
- Revenue
- GPRE $2,587,166,000.00
- ERAS N/A
- Revenue This Year
- GPRE N/A
- ERAS N/A
- Revenue Next Year
- GPRE $6.02
- ERAS N/A
- P/E Ratio
- GPRE N/A
- ERAS N/A
- Revenue Growth
- GPRE N/A
- ERAS N/A
- 52 Week Low
- GPRE $10.36
- ERAS $1.51
- 52 Week High
- GPRE $28.50
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- GPRE 47.33
- ERAS 46.40
- Support Level
- GPRE $10.36
- ERAS $2.51
- Resistance Level
- GPRE $11.37
- ERAS $2.97
- Average True Range (ATR)
- GPRE 0.54
- ERAS 0.21
- MACD
- GPRE 0.02
- ERAS -0.04
- Stochastic Oscillator
- GPRE 35.04
- ERAS 23.90
About GPRE Green Plains Inc.
Green Plains Inc manufactures and sells ethanol and ethanol byproducts in three segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities. The partnership segment provides fuel storage and transportation services.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.